FLUCELVAX® QUAD

Quadrivalent influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

Not all influenza vaccines are the same[1]

Help her make the choice.

FLUCELVAX® QUAD:

- **Designed to be an exact match** to WHO-selected strains[2-5†]

†May not predict clinical effects

Recommend FLUCELVAX® QUAD for patients 2 years and older[6]

WHO: World Health Organisation

PBS Information: This product is not listed on the National Immunisation Program (NIP) or the PBS.

Before prescribing, please review Product Information available at www.seqirus.com.au/products

MINIMUM PRODUCT INFORMATION Flucelvax® Quad (Inactivated Quadrivalent Influenza Vaccine (prepared in cell cultures)) - Suspension for injection. **Indication:** For the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine, for use in adults and children 2 years of age and older. **Contraindications:** Individuals with known severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine or to a previous dose of any influenza vaccine. **Precautions:** Treatment and supervision for anaphylactic reactions should be available. Antibody response in immunocompromised patients may be lower. Careful consideration for use in history of Guillain-Barré syndrome within 6 weeks of previous influenza vaccination. Postpone immunisation in patients with febrile illness or acute infection. A protective immune response may not be elicited in all vaccine recipients. **Use in Pregnancy (Category B1):** The safety of Flucelvax® Quad in pregnancy has not been assessed in clinical trials. There are no reproductive and developmental toxicity studies with Flucelvax® Quad. Reproductive and developmental toxicity data from cell-based trivalent influenza vaccine (TIVc) do not predict an increased risk of developmental abnormalities. **Use in Lactation:** Not been evaluated in nursing mothers. **Interactions:** No data available on co-administration with other vaccines. Based on clinical experience with TIVc, Flucelvax® Quad can be given at the same time as other vaccines (in separate limbs) (adverse reactions may be intensified). **Adverse Effects:** Local - pain, erythema. Systemic - headache, fatigue, irritability (children 2-6 years), upper respiratory tract infection, nasopharyngitis (See full PI). **Dosage and Administration:** Intramuscular injection only: single 0.5mL dose (children <9 years may require 2 doses - see full PI). **Presentation:** 0.5mL single-use syringe. Storage: Store at 2°C to 8°C; must not be frozen; protect from light. Based on Approved Product Information.

References: 1. ATAGI. Statement on the administration of seasonal influenza vaccines in 2022. www.health.gov.au/resources/publications/atagi-advice-on-seasonal-influenza-vaccines-in-2022 Accessed March 2022. **2.** Rajaram S *et al. Ther Adv Vaccines Immunother.* 2020;8:2515135520908121. **3.** CDC. Cell-based flu vaccines. Available from: www.cdc.gov/flu/prevent/cell-based.htm Accessed March 2022. **4.** Mabrouk T *et al. Dev Biol (Basel).* 2002;110:125–134. **5.** WHO. Influenza A(H3N2) lineage cell culture-derived CVVs for development and production of vaccines for use in the 2022 SH influenza season; Available from: https://cdn.who.int/media/docs/default-source/influenza/cvvs/cvv-southern-hemisphere-2022/a(h3n2)---cell-culture-derived.pdf Accessed March 2022. **6.** FLUCELVAX® QUAD Approved Product Information.

Seqirus (Australia) Pty Ltd Melbourne, Victoria. ABN: 66 120 398 067. www.seqirus.com.au. Seqirus Medical Information: 1800 642 865.

Date of preparation: March 2022. ANZ-QIVc-22-0027. 001351-A.

Seqirus™
A CSL COMPANY

FLUCELVAX®
QUAD

Quadrivalent influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

Not all influenza vaccines are the same[1]

Help him make the choice.

FLUCELVAX® QUAD:

- **Designed to be an exact match** to WHO-selected strains[2-5†]

†May not predict clinical effects

Recommend FLUCELVAX® QUAD for patients 2 years and older[6]

WHO: World Health Organisation

PBS Information: This product is not listed on the National Immunisation Program (NIP) or the PBS.

Before prescribing, please review Product Information available at www.seqirus.com.au/products

MINIMUM PRODUCT INFORMATION Flucelvax® Quad (Inactivated Quadrivalent Influenza Vaccine (prepared in cell cultures)) - Suspension for injection. **Indication:** For the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine, for use in adults and children 2 years of age and older. **Contraindications:** Individuals with known severe allergic reactions (e.g. anaphylaxis) to any component of the vaccine or to a previous dose of any influenza vaccine. **Precautions:** Treatment and supervision for anaphylactic reactions should be available. Antibody response in immunocompromised patients may be lower. Careful consideration for use in history of Guillain-Barré syndrome within 6 weeks of previous influenza vaccination. Postpone immunisation in patients with febrile illness or acute infection. A protective immune response may not be elicited in all vaccine recipients. **Use in Pregnancy (Category B1):** The safety of Flucelvax® Quad in pregnancy has not been assessed in clinical trials. There are no reproductive and developmental toxicity studies with Flucelvax® Quad. Reproductive and developmental toxicity data from cell-based trivalent influenza vaccine (TIVc) do not predict an increased risk of developmental abnormalities. **Use in Lactation:** Not been evaluated in nursing mothers. **Interactions:** No data available on co-administration with other vaccines. Based on clinical experience with TIVc, Flucelvax® Quad can be given at the same time as other vaccines (in separate limbs) (adverse reactions may be intensified). **Adverse Effects:** Local - pain, erythema. Systemic - headache, fatigue, irritability (children 2-6 years), upper respiratory tract infection, nasopharyngitis (See full PI). **Dosage and Administration:** Intramuscular injection only: single 0.5mL dose (children <9 years may require 2 doses - see full PI). **Presentation:** 0.5mL single-use syringe. Storage: Store at 2°C to 8°C; must not be frozen; protect from light. Based on Approved Product Information.

References: 1. ATAGI. Statement on the administration of seasonal influenza vaccines in 2022. www.health.gov.au/resources/publications/atagi-advice-on-seasonal-influenza-vaccines-in-2022 Accessed March 2022. **2.** Rajaram S *et al. Ther Adv Vaccines Immunother.* 2020;8:2515135520908121. **3.** CDC. Cell-based flu vaccines. Available from: www.cdc.gov/flu/prevent/cell-based.htm Accessed March 2022. **4.** Mabrouk T *et al. Dev Biol (Basel).* 2002;110:125–134. **5.** WHO. Influenza A(H3N2) lineage cell culture-derived CVVs for development and production of vaccines for use in the 2022 SH influenza season; Available from: https://cdn.who.int/media/docs/default-source/influenza/cvvs/cvv-southern-hemisphere-2022/a(h3n2)---cell-culture-derived.pdf Accessed March 2022. **6.** FLUCELVAX® QUAD Approved Product Information.

Seqirus (Australia) Pty Ltd Melbourne, Victoria. ABN: 66 120 398 067. www.seqirus.com.au. Seqirus Medical Information: 1800 642 865.

Date of preparation: March 2022. ANZ-QIVc-22-0027. 001351-B.

Seqirus™
A CSL COMPANY